Analysts expect Encana Corp (USA) (NYSE:ECA) to report $0.06 EPS on May, 2.They anticipate $0.21 EPS change or 140.00% from last quarter’s $-0.15 EPS. ECA’s profit would be $56.00 million giving it 46.21 P/E if the $0.06 EPS is correct. After having $0.09 EPS previously, Encana Corp (USA)’s analysts see -33.33% EPS growth. About 1.79M shares traded. Encana Corp (USA) (NYSE:ECA) has risen 14.90% since September 13, 2016 and is uptrending. It has outperformed by 4.97% the S&P500.
Myriad Genetics Incorporated (NASDAQ:MYGN) had a decrease of 4.03% in short interest. MYGN’s SI was 25.74 million shares in April as released by FINRA. Its down 4.03% from 26.82M shares previously. With 1.43M avg volume, 18 days are for Myriad Genetics Incorporated (NASDAQ:MYGN)’s short sellers to cover MYGN’s short positions. The SI to Myriad Genetics Incorporated’s float is 42.71%. About 162,828 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 14.42% since September 13, 2016 and is downtrending. It has underperformed by 24.35% the S&P500.
Investors sentiment increased to 1.1 in 2016 Q4. Its up 0.13, from 0.97 in 2016Q3. It is positive, as 31 investors sold Myriad Genetics, Inc. shares while 66 reduced holdings. 36 funds opened positions while 71 raised stakes. 77.40 million shares or 3.10% less from 79.87 million shares in 2016Q3 were reported. Opus Point Prtnrs Mngmt Ltd reported 13,907 shares. Great West Life Assurance Co Can has 0% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 9,213 shares. Tudor Investment Corp Et Al accumulated 47,033 shares or 0.02% of the stock. Nordea Invest Mgmt Ab invested 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Art Advisors Ltd Llc reported 48,900 shares. Aimz Inv Limited Liability Corporation has invested 0.65% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Rhumbline Advisers accumulated 76,457 shares. Castleark Ltd Liability Com accumulated 0.01% or 22,760 shares. Secor Cap Advsr Limited Partnership has 0.06% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 28,226 shares. Convergence Inv Ltd owns 16,378 shares. Jacobs Levy Equity Mngmt holds 221,630 shares. Fmr Ltd Liability Corporation invested 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Ngam Advisors Lp has invested 0.02% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Northwestern Mutual Wealth Management Communication owns 520 shares. Pnc Finance Gp has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN).
Since February 22, 2017, it had 1 buying transaction, and 0 insider sales for $111,930 activity. $111,930 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) shares were bought by HENDERSON JOHN T.
Myriad Genetics, Inc. is a molecular diagnostic company. The company has market cap of $1.20 billion. The Firm is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It has a 17.67 P/E ratio. The Firm operates through two divisions: diagnostics and other.
Among 17 analysts covering Myriad Genetics (NASDAQ:MYGN), 3 have Buy rating, 4 Sell and 10 Hold. Therefore 18% are positive. Myriad Genetics had 32 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Underweight” rating given on Wednesday, August 10 by Morgan Stanley. The company was initiated on Thursday, January 7 by Deutsche Bank. As per Wednesday, August 10, the company rating was downgraded by Barclays Capital. As per Wednesday, August 10, the company rating was maintained by UBS. As per Wednesday, August 10, the company rating was downgraded by Wells Fargo. On Wednesday, November 4 the stock rating was maintained by Mizuho with “Neutral”. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Market Perform” rating by Wells Fargo on Tuesday, August 25. The firm has “Hold” rating by Gabelli given on Wednesday, August 10. Bank of America downgraded the stock to “Underperform” rating in Friday, July 29 report. On Tuesday, December 8 the stock rating was upgraded by Goldman Sachs to “Neutral”.
